RE:RE:RE:PMN Announces Strategic Priorities for 2021They're getting paid to never say that, which is why that whole news release is such a BS sandwich.
None of the FDA advisory panel experts voted yes on whether the PRIME results supported evidence of aducanumab’s efficacy so FDA approval would have to be based on another question – “has the applicant presented strong evidence of a pharmacodynamic effect of aducanumab on Alzheimer’s disease pathophysiology?” – five experts voted yes, while six voted uncertain, representing a small win for Biogen.
Poor efficacy is why Promis should not be joined at the hip to Aducanumab but rather be hyping a basket amyloid drug approach. It's not too late for Gene and Elliot to fix this mistake, and it's not like they don't have the time or the incentive to do so.